Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib

Open access

Abstract

PURPOSE: BIM is essential for the response to tyrosine-kinase inhibitors (TKI) in chronic myeloid leukaemia (CML) patients. Recently, a deletion polymorphism in intron 2 of the BIM gene was demonstrated to confer an intrinsic TKI resistance in Asian patients. The present study aimed at identifying mutations in the BIM sequence that could lead to imatinib resistance independently of BCR-ABL mutations. EXPERIMENTAL DESIGN: BIM coding sequence analysis was performed in 72 imatinib-treated CML patients from a French population of our centre and in 29 healthy controls (reference population) as a case-control study. Real-time quantitative PCR (RT qPCR) was performed to assess Bim expression in our reference population. RESULTS: No mutation with amino-acid change was found in the BIM coding sequence. However, we observed a silent single nucleotide polymorphism (SNP) c465C>T (rs724710). A strong statistical link was found between the presence of the T allele and the high Sokal risk group (p = 0.0065). T allele frequency was higher in non responsive patients than in the reference population (p = 0.0049). Similarly, this T allele was associated with the mutation frequency on the tyrosine kinase domain of BCR-ABL (p<0.001) and the presence of the T allele significantly lengthened the time to achieve a major molecular response (MMR). Finally, the presence of the T allele was related to a decreased basal expression of the Bim mRNA in the circulating mononuclear cells of healthy controls. CONCLUSION: These results suggest that the analysis of the c465C>T SNP of BIM could be useful for predicting the outcome of imatinib-treated CML patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0078582

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Relation between the c465C>T genotypes and the Sokal risk score or imatinib response. a: BIMEL coding region was sequenced in the cDNA from 72 CML patients and 29 healthy donors. The c465C>T genotype frequency (in %) was plotted for the healthy controls and the whole patient cohort. In this cohort, 32 were responders (optimal response) while 40 “non responders” exhibited sub-optimal or failure to first line imatinib treatment. Each bar represents the frequency percentage of the corresponding genotype in each group. b: cDNAs from 48 patients were sequenced for the BIMEL coding region and the frequency of C/C or C/T+T/T genotypes was plotted for risk subcategories according to the Sokal score: <0.8 characterizes the low risk group, >1.2 the high risk group and 0.8<–<1.2 the intermediate group. The bars represent the frequency (in percentage) of the C/C (light grey) and C/T+T/T (dark grey) genotype. The number of cases was indicated above each bar?
Figure 1 Relation between the c465C>T genotypes and the Sokal risk score or imatinib response. a: BIMEL coding region was sequenced in the cDNA from 72 CML patients and 29 healthy donors. The c465C>T genotype frequency (in %) was plotted for the healthy controls and the whole patient cohort. In this cohort, 32 were responders (optimal response) while 40 “non responders” exhibited sub-optimal or failure to first line imatinib treatment. Each bar represents the frequency percentage of the corresponding genotype in each group. b: cDNAs from 48 patients were sequenced for the BIMEL coding region and the frequency of C/C or C/T+T/T genotypes was plotted for risk subcategories according to the Sokal score: <0.8 characterizes the low risk group, >1.2 the high risk group and 0.8<–<1.2 the intermediate group. The bars represent the frequency (in percentage) of the C/C (light grey) and C/T+T/T (dark grey) genotype. The number of cases was indicated above each bar?CC BY · PubMed Central
Figure 2 Relation between the C/C or T/T plus C/T BIM genotypes and the achievement of MMR. a: cDNAs from 64 patients followed in the laboratory for their Bcr-Abl expression were sequenced for the BIMEL coding region. The number of patients achieving a MMR before or after 18 months (left panel) or 24 months (right panel) was plotted as a function of the c465C>T genotype: C/C (white bars) or C/T plus T/T (grey bars). p indicates significance with the chi-square test. b: Kaplan-Meier analysis of the achievement of a MMR. The figure represents the probability to achieve a MMR (in %) as a function of the treatment duration (in months) for patients with the C/C genotype (continuous line) or patients with the C/T or T/T genotype (dotted line). c: cDNAs from 37 resistant patients were sequenced for both the BCR-ABL tyrosine kinase domain (TKD) and BIMEL coding region. The frequency of patients with non mutated or mutated TKD was plotted as a function of the c465C>T genotype. The numbers above the bars indicate the sample size. The p value was calculated using the Chi-square test.
Figure 2 Relation between the C/C or T/T plus C/T BIM genotypes and the achievement of MMR. a: cDNAs from 64 patients followed in the laboratory for their Bcr-Abl expression were sequenced for the BIMEL coding region. The number of patients achieving a MMR before or after 18 months (left panel) or 24 months (right panel) was plotted as a function of the c465C>T genotype: C/C (white bars) or C/T plus T/T (grey bars). p indicates significance with the chi-square test. b: Kaplan-Meier analysis of the achievement of a MMR. The figure represents the probability to achieve a MMR (in %) as a function of the treatment duration (in months) for patients with the C/C genotype (continuous line) or patients with the C/T or T/T genotype (dotted line). c: cDNAs from 37 resistant patients were sequenced for both the BCR-ABL tyrosine kinase domain (TKD) and BIMEL coding region. The frequency of patients with non mutated or mutated TKD was plotted as a function of the c465C>T genotype. The numbers above the bars indicate the sample size. The p value was calculated using the Chi-square test.CC BY · PubMed Central
Figure 3 Relation between the C/C or C/T plus T/T BIM genotypes and the basal expression of Bim. The cDNA from mononuclear cells of 29 healthy controls was analysed for BIM mRNA expression by quantitative RT-PCR and sequencing of the BIM coding region. The BIM expression (relative to β actin) was plotted as a function of the c465C>T genotype comparing the C/C to the C/T and T/T genotypes. The p value was calculated using the Mann-Whitney test.
Figure 3 Relation between the C/C or C/T plus T/T BIM genotypes and the basal expression of Bim. The cDNA from mononuclear cells of 29 healthy controls was analysed for BIM mRNA expression by quantitative RT-PCR and sequencing of the BIM coding region. The BIM expression (relative to β actin) was plotted as a function of the c465C>T genotype comparing the C/C to the C/T and T/T genotypes. The p value was calculated using the Mann-Whitney test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 2

  1. International HapMap project website. Available http://hapmap.ncbi.nlm.nih.gov/ Accessed 2008
  2. dbSNP website. Available http://www.ncbi.nlm.nih.gov/SNP/. Accessed 2008

Cited by

See all 37

Metadata

Authors
Augis, V., Airiau, K., Josselin, M., Turcq, B., Mahon, F.-X., & Belloc, F.
Affiliations
Inserm (FR)
Corresponding author
Augis, Vanessa
Venue
PLoS ONE
Published
2013-11-05
Volume
8
Issue
11
Pages
e78582
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2079281117
Cited by
35
References
25
Citations by year
2026: 3 · 2024: 4 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 5 · 2016: 5 · 2015: 5 · 2014: 4
FWCI
3.35
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ligue Contre le Cancer
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
chronic myeloid leukemia, imatinib, single nucleotide polymorphisms, major molecular response, imatinib resistance, BCR-ABL mutations, tyrosine kinase inhibitors, prognostic factors
MeSH terms
Imatinib Mesylate, Bcl-2-Like Protein 11, Adolescent, Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Benzamides, Child, Child, Preschool, Female, Gene Frequency, Humans, Leukocytes, Mononuclear, Male, Membrane Proteins, Middle Aged, Piperazines, Proto-Oncogene Proteins, Pyrimidines, RNA, Messenger, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gene Expression, Case-Control Studies, Fusion Proteins, bcr-abl, Polymorphism, Single Nucleotide, Apoptosis Regulatory Proteins, Biomarkers, Pharmacological, Mutation Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib. https://app.cochat.ai/papers/10.1371/journal.pone.0078582
The paper
Augis, V., Airiau, K., Josselin, M., Turcq, B., Mahon, F.-X., & Belloc, F. (2013). A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib. PLoS ONE. https://doi.org/10.1371/journal.pone.0078582

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.